Henk Lang

Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers

Hui Zhao, Ker Yu, Xuesai Zhang, 2019, Acta Pharmacologica Sinica.

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL

E. Iwanowicz, R. Christopherson, O. G. Best, 2021, EJHaem.

The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro

E. Iwanowicz, R. Christopherson, O. G. Best, 2022, bioRxiv.

Potent ClpP agonists with anticancer properties bind with improved structural complementarity and alter the mitochondrial N-terminome.

A. Gingras, W. Houry, E. Iwanowicz, 2022, Structure.

Characterization of TR‐107, a novel chemical activator of the human mitochondrial protease ClpP

W. Houry, E. Iwanowicz, C. Der, 2022, bioRxiv.

Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox.

Maurizio Pellecchia, Daniel S Sem, H. Villar, 2004, Chemistry & biology.

Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers

Hui Zhao, Ker Yu, Qingrou Li, 2018, Acta Pharmacologica Sinica.